AU2021390209A1 - Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression - Google Patents

Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression Download PDF

Info

Publication number
AU2021390209A1
AU2021390209A1 AU2021390209A AU2021390209A AU2021390209A1 AU 2021390209 A1 AU2021390209 A1 AU 2021390209A1 AU 2021390209 A AU2021390209 A AU 2021390209A AU 2021390209 A AU2021390209 A AU 2021390209A AU 2021390209 A1 AU2021390209 A1 AU 2021390209A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021390209A
Other languages
English (en)
Other versions
AU2021390209A9 (en
Inventor
Jang-Ho CHA
Thomas Faller
Baltazar Gomez-Mancilla
Dimitris PAPANICOLAOU
Carmen-Gabriela SERBAN
Florian Von Raison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2021390209A1 publication Critical patent/AU2021390209A1/en
Publication of AU2021390209A9 publication Critical patent/AU2021390209A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021390209A 2020-12-04 2021-12-03 Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression Abandoned AU2021390209A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063121508P 2020-12-04 2020-12-04
US202063121513P 2020-12-04 2020-12-04
US63/121,513 2020-12-04
US63/121,508 2020-12-04
PCT/IB2021/061268 WO2022118264A1 (en) 2020-12-04 2021-12-03 Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression

Publications (2)

Publication Number Publication Date
AU2021390209A1 true AU2021390209A1 (en) 2023-06-22
AU2021390209A9 AU2021390209A9 (en) 2024-10-31

Family

ID=78844691

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021390209A Abandoned AU2021390209A1 (en) 2020-12-04 2021-12-03 Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression

Country Status (10)

Country Link
US (1) US20240041853A1 (enExample)
EP (1) EP4255419A1 (enExample)
JP (1) JP2023551943A (enExample)
KR (1) KR20230116865A (enExample)
AU (1) AU2021390209A1 (enExample)
CA (1) CA3203144A1 (enExample)
IL (1) IL303357A (enExample)
MX (1) MX2023006567A (enExample)
TW (1) TW202237103A (enExample)
WO (1) WO2022118264A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119654149A (zh) * 2022-06-02 2025-03-18 诺华股份有限公司 用于在治疗抑郁障碍中使用的奥法地尔的皮下施用和给药方法
WO2025120013A1 (en) * 2023-12-06 2025-06-12 Novartis Ag Compositions and methods for treating depression disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
US9540324B2 (en) * 2013-09-26 2017-01-10 Luc Therapeutics, Inc. Selective octahydro-cyclopenta[C] pyrrole negative modulators of NR2B
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
CA2970958A1 (en) * 2014-12-23 2016-06-30 Cerecor, Inc. Compounds, compositions and methods
MX2018004256A (es) * 2015-10-14 2018-05-16 Squibb Bristol Myers Co Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
CA3001894A1 (en) * 2015-10-14 2017-04-20 Bristol-Myers Squibb Company Selective nr2b antagonists

Also Published As

Publication number Publication date
KR20230116865A (ko) 2023-08-04
WO2022118264A1 (en) 2022-06-09
CA3203144A1 (en) 2022-06-09
US20240041853A1 (en) 2024-02-08
AU2021390209A9 (en) 2024-10-31
IL303357A (en) 2023-08-01
JP2023551943A (ja) 2023-12-13
MX2023006567A (es) 2023-06-16
EP4255419A1 (en) 2023-10-11
TW202237103A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
JP2015516395A (ja) 新規方法
EP4499074A1 (en) 5-meo-dtm for the treatment of bipolar disorder
US20200113882A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
US20240366582A1 (en) Treatment of raynaud's disease
EP2958573A2 (en) Pharmaceutical formulations of nitrite and uses thereof
EP4255419A1 (en) Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression
CN104582793A (zh) 用拉喹莫德和氨吡啶的组合治疗多发性硬化症
Himmelhoch et al. The role of trazodone in the treatment of depressed cardiac patients
JPH09504798A (ja) 早発性射精の治療におけるアルフゾシンまたはテラゾシンの使用
US20250205191A1 (en) R(-)-mdma compositions and methods of treatment
TW202402271A (zh) Ｎｒ２ｂ—ｎｍｄａ受體ｎａｍ用於憂鬱障礙的劑量
TW202440106A (zh) 用於治療勃起障礙之化合物
US20240261238A1 (en) Method of treating drug resistant epilepsy
WO2008109343A1 (en) Methods of treating bipolar disorder and memory and/or cognitive impairment associated therewith with (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate
CN116744922A (zh) Nr2b-nmda受体nam在治疗抑郁症中的剂量方案
Li et al. From heartbreak to left bundle branch block: a case of amitriptyline overdose
AU2024238367A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period